News Archive

16 April 2015

Merck Animal Health Launches IDAL® 2G Vaccination Device for Pigs

Second-Generation Needle-Free Device Includes New Features Including Bluetooth Compatibility and App to Monitor Data

MADISON, NJ April 16, 2015 – Merck Animal Health (known as MSD Animal Health outside the USA and Canada) today announced the launch of the IDAL® 2G vaccination device for pigs. The second generation of Merck Animal Health’s needle-free IDAL vaccine delivery system, IDAL 2G has additional features that give the user more information and make the system easier to use.

A needle-free device, IDAL 2G administers a fixed (0.2 mL), low-volume dose of vaccine into the dermis of any size pig, including sows. Needle-free delivery allows for additional vaccination options in pigs, providing flexibility for the user, particularly when vaccinating large groups of pigs.

The IDAL 2G reduces stress on pigs, which can improve animal welfare, while absence of needles positively impacts biosecurity due to prevention of disease transmission and food safety.

The new IDAL 2G can send vaccination data directly to a tablet or smart phone (Apple® or select versions of Android®) through Bluetooth® technology. An exclusive App allows users to monitor and manage all of the data contained within the vaccinator, such as doses per bottle; total doses remaining; doses to next service and maintenance needed. Additionally, a larger display window allows quick access to important information, and a redesigned, easy-to-clean, briefcase keeps all of the IDAL 2G components organized.

“The first IDAL vaccine injector gave swine producers a revolutionary tool that made vaccination easier and more efficient,” said Rika Jolie, Merck Animal Health. “We are proud to introduce the next generation with IDAL 2G, which includes new attributes that will make it easier for producers to track injector readiness, performance and maintenance.”

Merck Animal Health currently offers three intradermal swine vaccines for administration with IDAL 2G, including PORCILIS® M Hyo ID ONCE, PORCILIS® PRRS and PORCILIS® Begonia IDAL, with additional vaccines under development.

The original IDAL vaccinator can be upgraded the IDAL 2G. Producers and veterinarians can contact their Merck Animal Health representative for more information.

About Merck Animal Health
Today's Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn and Twitter at @MerckAH.

Merck forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).